Edison and his team ran the trial using liraglutide, a daily injection sold under the brand names Victoza for diabetes and Saxenda for weight loss, because its similar to the GLP-1 hormone found in humans, he said, and it was on the market for diabetes when the study started about a decade ago
doi: 10.1210/endo.131.1.1612006
Increased total Nrf2 and phosphorylated Nrf2 protein levels in cortical tissue, and elevated Nrf2/NeuN and p-Nrf2/NeuN-positive neuron counts
Moreover, p53, a key tumour suppressor, exerts dual regulatory effects on ROS-induced apoptosis
There is limited direct evidence for this specific stack in controlled studies, and clinicians considering it should weigh the additive mechanistic logic against the absence of human safety data for the combination